{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/candida-female-genital/management/during-pregnancy/","result":{"pageContext":{"chapter":{"id":"d143d272-2856-5fad-95fe-708b221847f0","slug":"during-pregnancy","fullItemName":"Scenario: During pregnancy","depth":2,"htmlHeader":"<!-- begin field 1cde2016-94c3-46d1-840c-f7cf856f10dd --><h2>Scenario: During pregnancy</h2><!-- end field 1cde2016-94c3-46d1-840c-f7cf856f10dd -->","summary":"Covers the management of vulvovaginal candidiasis in pregnant women.","htmlStringContent":"<!-- begin item 7e1998ad-9505-41db-8b42-e8b8da99a039 --><!-- begin field e4c97ad3-918f-4e47-8982-acbc0156a9ce --><p>From age 12 years onwards (Female).</p><!-- end field e4c97ad3-918f-4e47-8982-acbc0156a9ce --><!-- end item 7e1998ad-9505-41db-8b42-e8b8da99a039 -->","topic":{"id":"99e20f18-68df-560d-b5d3-b6ec31ccad61","topicId":"1a8f74c5-56a3-4356-a328-97bd2f790f35","topicName":"Candida - female genital","slug":"candida-female-genital","lastRevised":"Last revised in May 2017","chapters":[{"id":"de1ba63a-d3be-5e38-9afa-2decfb6a4104","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"70e5dc95-dca6-5aed-ba02-7677e5595791","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7785eebb-7adf-5829-8438-054465d94780","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"17acaa38-dc82-5062-9b9e-b70e43844f09","slug":"changes","fullItemName":"Changes"},{"id":"3fde567e-3066-57d8-be3e-016c389f8b94","slug":"update","fullItemName":"Update"}]},{"id":"7bdd785b-dd70-5bde-a56b-ece7a71c1890","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2aea51d9-2817-5901-8b3f-003e41a1f1b9","slug":"goals","fullItemName":"Goals"},{"id":"16c71775-c8a9-58f1-b6e8-00d83ea3e32a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"584f77ef-93e6-5c84-93b4-8331fed80193","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ffb6e4fa-b86a-5191-9bbb-c113c86952b6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cc13b04c-c8b4-5403-a61e-10f784bc17de","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ba1a16f-d8bd-55bc-8208-17beaddd9264","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"d90c278f-fcf0-5c7c-aeab-b0decc2194dd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5d851a40-f1f9-50de-b7de-3e374a862b45","slug":"definition","fullItemName":"Definition"},{"id":"51060b0d-4f1d-5133-9645-6efc6b9ca9d8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c7dd35c5-dc87-55a0-b15e-5fd3c5f79ede","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bcbc381a-db1c-5df4-a8fa-cb1ce02a4ab3","slug":"complications","fullItemName":"Complications"},{"id":"2ec519a6-61da-53cb-b5c6-e53420e1f175","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"1296609f-72a1-5634-918b-eb0f9bf2b217","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"197fc582-d823-5341-813b-4d48a895ac84","slug":"assessment","fullItemName":"Assessment"},{"id":"7fa609e6-64b1-5e1e-a2fe-9d8aaae57662","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b7ed2787-e953-5da0-ba29-6ad5d5aa7138","fullItemName":"Management","slug":"management","subChapters":[{"id":"0d8e43cc-e312-572a-97eb-50ab1223bf29","slug":"uncomplicated-infection","fullItemName":"Scenario: Uncomplicated infection"},{"id":"20ef6f32-4f35-577b-af2b-0479dafd7a6f","slug":"severe-infection","fullItemName":"Scenario: Severe infection"},{"id":"19018671-1df6-546c-a24e-c0277342e2e1","slug":"recurrent-infection","fullItemName":"Scenario: Recurrent infection"},{"id":"0f525c4d-623c-5b02-9045-c7f9c57692e4","slug":"diabetes-or-immunocompromised","fullItemName":"Scenario: Diabetes or immunocompromised"},{"id":"d143d272-2856-5fad-95fe-708b221847f0","slug":"during-pregnancy","fullItemName":"Scenario: During pregnancy"}]},{"id":"fa8e2e27-5ea4-5088-86f8-65ffd101ec26","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a11071ae-b868-56f6-a390-4809b91594ea","slug":"choice-of-antifungals","fullItemName":"Choice of antifungals"},{"id":"169ff7be-fabd-556e-bdf3-92c30e390f3d","slug":"intravaginal-antifungals","fullItemName":"Intravaginal antifungals"},{"id":"cca352b0-a363-5b43-97d2-9df0dbf242b6","slug":"oral-fluconazole","fullItemName":"Oral fluconazole"},{"id":"754e0483-3f11-5510-9b98-7f8c44679e56","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"2ae3a41b-64fa-5372-baba-bb8c04e033d8","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"dd75ee8e-5efd-51c0-bcc2-3af7ee1253e7","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"74d9d85c-590f-5e29-a202-78d94a6f747f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d7a69713-bc5d-57da-9132-ff07c7fef62c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a8d93477-c70c-5177-92d7-e96545a6b2f7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4841d69e-1e2b-5aec-9c3b-1ea8cd8bbf08","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b3113b9f-1b0e-5987-99b4-e616eb6d128a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e41c5da-d9a8-5c0d-bb7f-f68cda4acb05","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6eb1b4a4-5ae4-5a59-8ca6-6434652b9454","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b7ed2787-e953-5da0-ba29-6ad5d5aa7138","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"1c353fc8-cd93-536d-8047-e927052714e4","slug":"initial-management","fullItemName":"Initial management","depth":3,"htmlHeader":"<!-- begin field 6cd10037-c70b-4f9f-bd90-5404fa0b645e --><h3>How should I manage a woman with vulvovaginal candidiasis who is pregnant?</h3><!-- end field 6cd10037-c70b-4f9f-bd90-5404fa0b645e -->","summary":null,"htmlStringContent":"<!-- begin item a8c85777-e5e2-4c83-80ed-2a7919152f5b --><!-- begin field 6edeec4a-ae6d-47ae-b8e9-b4a9e3d9d78c --><ul><li><strong>Prescribe antifungal treatment.</strong><ul><li><strong>For women and girls aged 16 years and older, </strong>treat with intravaginal clotrimazole or miconazole for at least 7 days. Do not prescribe an oral antifungal drug (fluconazole or itraconazole).<ul><li>Advise that care should be taken when using an applicator to avoid physical damage to the cervix. Some women prefer to insert pessaries by hand when pregnant.</li><li><strong>If there are vulval symptoms,</strong> consider prescribing a topical imidazole in addition to intravaginal clotrimazole or miconazole. Options include clotrimazole 1% or 2% cream applied 2–3 times a day, or ketoconazole 2% cream applied 1–2 times a day (for adults aged 18 years and older).</li></ul></li><li><strong>For girls </strong><strong>aged 12–15 years</strong><strong>,</strong> consider prescribing topical clotrimazole 1% or 2% to be applied 2–3 times a day, or seek specialist advice. Do not prescribe an intravaginal or oral antifungal.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/prescribing-information/\">Prescribing information</a> for detailed information on intravaginal and topical antifungals, including information on contraindications and cautions, adverse effects, and drug interactions.</li></ul></li><li><strong>Advise the woman:</strong><ul><li>To return if symptoms have not resolved within 7–14 days. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/during-pregnancy/#treatment-failure-in-pregnancy\">Managing&nbsp;treatment failure</a> for more management information.</li><li>On measures to aid symptom relief and prevent recurrence. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/during-pregnancy/#general-advice-on-self-management\">Self-management advice</a> for more information.</li></ul></li><li><strong>Follow-up and test of cure are <em>not</em> necessary if symptoms resolve.</strong></li><li><strong>Do not routinely treat </strong><strong>an asymptomatic sexual partner.</strong><ul><li>If the male partner of a woman with vulvovaginal candidiasis has balanitis (characterized by erythematous areas on the glans of the penis, pruritus, and/or irritation), see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/balanitis/\">Balanitis</a> for management information.</li></ul></li></ul><!-- end field 6edeec4a-ae6d-47ae-b8e9-b4a9e3d9d78c --><!-- end item a8c85777-e5e2-4c83-80ed-2a7919152f5b -->","subChapters":[{"id":"8efa6354-ac7a-518f-9bd4-c6d8b6910067","slug":"basis-for-recommendation-4e6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e516f231-7f8f-4413-933a-51b4a1db04c3 --><h4>Basis for recommendation</h4><!-- end field e516f231-7f8f-4413-933a-51b4a1db04c3 -->","summary":null,"htmlStringContent":"<!-- begin item 4e6e7d3b-e72d-4aa3-86a7-833f9868280a --><!-- begin field 2f97ebfa-34f5-4157-9f3d-f818c6ea8040 --><h5>Antifungal treatment</h5><ul><li><strong>Choice of treatment</strong><ul><li>Oral antifungals are not recommended for use in pregnant women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">van Schalkwyk, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">NICE, 2016</a>].</li><li>Expert opinion in the British National Formulary (BNF) is that vulvovaginal candidiasis in pregnancy can be treated with an intravaginal imidazole (and a topical imidazole for vulvitis) for a duration of about 7 days [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li><li>CKS recommends intravaginal clotrimazole or miconazole as there is extensive experience with their use. The manufacturers state that during pregnancy:<ul><li>Clotrimazole can be used, but only under the supervision of a doctor or midwife [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015b</a>].</li><li>Miconazole should be used if the potential benefits outweigh the risks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015e</a>].</li><li>Econazole should be used if the doctor considers it to be necessary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016c</a>].</li><li>Fenticonazole can be used if the doctor considers it essential to the welfare of the woman [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2010</a>].</li></ul></li></ul></li><li><strong>Managing vulval symptoms</strong><ul><li>This recommendation is based on the BNF, which states that vaginal applications may be supplemented with a topical antifungal cream for vulvitis and to treat other superficial sites of infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>].</li></ul></li><li><strong>Managing girls </strong><strong>aged 12–15 years</strong><ul><li>This recommendation is based on the fact that management decisions for this age group are not straightforward:<ul><li>Intravaginal antifungal pessaries and cream are not recommended for pre-pubertal girls [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>].</li><li>The BNF for Children states that treatment with an external cream may be more appropriate in this age group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>]. The option of seeking specialist advice is based on what CKS considers to be good clinical practice.</li><li>Oral fluconazole is not licensed for treating vulvovaginal candidiasis in children younger than 16 years of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>].</li><li>Oral itraconazole is not licensed for use in children (age not specified by the manufacturer) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>].</li></ul></li></ul></li></ul><h5>Follow-up and test of cure not necessary </h5><ul><li>In the expert opinion of the British Association of Sexual Health and HIV (BASHH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>] and the US Centers for Disease Control and Prevention (CDC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], follow up and test of cure are unnecessary unless symptoms are persistent or recurrent.</li></ul><h5>Advice</h5><ul><li>The recommendation to advise the person to return if symptoms have not resolved within 7–14 days is based on expert opinion in review articles, which states that treatment failure is considered to have occurred if symptoms do not resolve within 7–14 days of antifungal treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Sobel et al, 1998</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Watson et al, 2002</a>].</li><li>The recommendation to advise on measures to aid symptom relief is based on what CKS considers to be good clinical practice.</li></ul><h5>Not routinely treating an asymptomatic sexual partner</h5><ul><li>In the expert opinion of BASHH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>] and the CDC [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], uncomplicated vulvovaginal candidiasis is not usually acquired through sexual intercourse, and the available data do not support treating asymptomatic male partner of women with vulvovaginal candidiasis.</li><li>However, a small percentage of male partners will develop balanitis, and they should be managed appropriately [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>].</li></ul><!-- end field 2f97ebfa-34f5-4157-9f3d-f818c6ea8040 --><!-- end item 4e6e7d3b-e72d-4aa3-86a7-833f9868280a -->","subChapters":[]}]},{"id":"ccb62cfe-6f62-515b-8b1b-e55a7925d45f","slug":"general-advice-on-self-management","fullItemName":"General advice on self-management","depth":3,"htmlHeader":"<!-- begin field e33be2fb-cfc3-4131-a720-d5bd60bf5ac3 --><h3>What advice on self-management should I give?</h3><!-- end field e33be2fb-cfc3-4131-a720-d5bd60bf5ac3 -->","summary":null,"htmlStringContent":"<!-- begin item 275a1c89-4251-453f-8313-2258b47188bf --><!-- begin field 8ce6738a-d72f-4c7d-b824-50e882b5bbba --><ul><li><strong>Advise the woman to:</strong><ul><li>Avoid the following potential predisposing factors:<ul><li>Washing and cleaning the vulval area with soap or shower gels (including those containing perfume and antiseptics [such as tea tree oil]), wipes, and 'feminine hygiene' products.</li><li>Cleaning the vulval area more than once a day.</li><li>Washing underwear in biological washing powder and using fabric conditioners.</li><li>Vaginal douching.</li><li>Wearing tight-fitting and/or non-absorbent clothing.</li></ul></li><li>Wash the vulval area with a soap substitute — this should be used externally and not more than once a day.</li><li>Use a simple emollient to moisturise the vulval area.</li><li>Consider using probiotics (such as live yoghurts) orally or topically to relieve symptoms.  </li></ul></li></ul><!-- end field 8ce6738a-d72f-4c7d-b824-50e882b5bbba --><!-- end item 275a1c89-4251-453f-8313-2258b47188bf -->","subChapters":[{"id":"a92697eb-075c-5c1c-b032-3351350f3fdb","slug":"basis-for-recommendation-8ed","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fabfda9b-185a-4265-be4c-13c8b7b78966 --><h4>Basis for recommendation</h4><!-- end field fabfda9b-185a-4265-be4c-13c8b7b78966 -->","summary":null,"htmlStringContent":"<!-- begin item 8ed445d8-3f2b-488d-b81b-53162709c196 --><!-- begin field 4ca4d9c5-5fbe-456f-9039-fc5dd0455b09 --><h5>Avoiding potential predisposing factors</h5><ul><li>Expert opinion in UK guidelines is that local irritants (such as soaps, shower gels, and ‘feminine hygiene’ products) and tight-fitting, synthetic clothing can predispose to (or exacerbate) symptomatic vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>], although the evidence for these is limited, conflicting, or absent.</li><li>Evidence from observational studies suggests that vaginal douching increases the risk of infection and other adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].</li></ul><h5>General care of the vaginal skin</h5><ul><li>The advice on the general care of vulval skin and the use of a simple emollient is based on expert advice in the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>The management of vulval skin disorders</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCOG, 2011</a>].</li></ul><h5>Probiotics</h5><ul><li>The British Medical Journal (BMJ) Clinical Evidence review on <em>Vulvovaginal candidiasis</em> (search date: October 2013) did not identify any randomized controlled trials (RCTs) comparing yoghurt containing <em>Lactobacillus acidophilus </em>with other interventions for the treatment of women with acute vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].<ul><li>One small RCT (n = 55) that compared oral <em>L acidophilus </em>with placebo at 1 month when given after a single dose of oral fluconazole (150 mg) found that oral <em>L acidophilus</em>:<ul><li>Decreased vaginal discharge compared with placebo (3/29 [10%] with oral <em>L acidophilus </em>compared with 9/26 [35%] with placebo; P = 0.03).</li><li>Reduced the presence of yeast detected by culture compared with placebo (3/29 [10%] with oral <em>L acidophilus </em>compared with 10/26 [39%] with placebo; P = 0.01).</li></ul></li><li>There was no evidence of serious harm, but one systematic review (which did not identify any suitable RCTs) stated that oral yoghurt may cause gastrointestinal disturbance in people with lactose intolerance.</li><li>The authors of the BMJ review concluded that the following should be considered:<ul><li>Applying yoghurt intravaginally may be embarrassing and uncomfortable for some women.</li><li>Although different yoghurts can be purchased, their compositions vary, and their effects may differ.</li><li>The effect of alterations in vaginal pH that may occur with intravaginal yoghurt use is unknown.</li></ul></li></ul></li><li>CKS recommends advising the woman to consider using probiotics because although there is no evidence that they are effective, there is no evidence of (or concerns about) serious adverse effects.</li></ul><h5>Tea tree oil</h5><ul><li>The BMJ Clinical Evidence review on <em>Vulvovaginal candidiasis</em> (search date: October 2013) did not identify any RCTs comparing intravaginal tea tree oil with other interventions for the treatment of women with acute vulvovaginal candidiasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Lopez, 2015</a>].<ul><li>One systematic review (which did not identify any suitable RCTs) stated that topical tea tree oil can cause skin irritation and a severe allergic rash.</li><li>One case report found that topical tea tree oil was associated with systemic hypersensitivity reaction.</li></ul></li><li>Expert opinion in the joint Faculty of Sexual and Reproductive Healthcare (FSRH) and the British Association of Sexual Health and HIV (BASHH) guideline <em>Management of vaginal discharge in non-genitourinary medicine settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>] and the joint Royal College of General Practitioners (RCGP) Sex, Drugs and HIV Task Group and BASHH guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>] is that there is currently insufficient evidence to recommend the use of tea tree oil in the management of vulvovaginal candidiasis.</li></ul><!-- end field 4ca4d9c5-5fbe-456f-9039-fc5dd0455b09 --><!-- end item 8ed445d8-3f2b-488d-b81b-53162709c196 -->","subChapters":[]}]},{"id":"ff21cfe6-db58-520f-80ef-a704daf7f90b","slug":"treatment-failure-in-pregnancy","fullItemName":"Treatment failure in pregnancy","depth":3,"htmlHeader":"<!-- begin field d007d918-7c74-45e1-b582-d981832cc8f9 --><h3>How should I manage treatment failure in a pregnant woman?</h3><!-- end field d007d918-7c74-45e1-b582-d981832cc8f9 -->","summary":null,"htmlStringContent":"<!-- begin item d4f24006-d45c-4dfb-87ea-7617554d1ed8 --><!-- begin field 55d7b310-3f54-4a43-ad09-5c82dee3f017 --><ul><li><strong>If symptoms have not resolved within 7–14 days of initial treatment:</strong><ul><li><strong>Confirm that the <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/during-pregnancy/#initial-management\">initial treatment</a> was used as recommended, </strong>but be aware that:<ul><li>Vulvovaginal candidiasis is common (and recurs frequently) in women who are immunocompromised.</li><li>Topical treatments can cause vulvovaginal irritation, which may be mistaken for treatment failure. </li></ul></li><li><strong>Reassess </strong><strong>for other <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/background-information/risk-factors/\">predisposing factors</a></strong> and remove or control as far as possible.</li><li><strong>Consider<em> </em></strong><strong><a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/differential-diagnosis/\">alternative diagnoses</a><em>. </em></strong>If appropriate:<ul><li>Send a vaginal specimen for microscopy, culture, and sensitivity. This may identify a moderate/heavy growth of <em>Candida albicans</em>, non-albicans <em>Candida </em>species, or a <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/differential-diagnosis/\">mixed infection</a>.</li><li>Consider measuring vaginal pH (if possible) to assess the likelihood of symptoms being due to <em>Candida </em>(pH less than or equal to 4.5), bacterial vaginosis (pH above 4.5), or <em>Trichomonas vaginalis </em>(pH above 4.5).</li><li>Arrange other <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/assessment/\">investigations</a> as clinically indicated.</li></ul></li><li><strong>Treat the infection.</strong><ul><li><strong>If symptoms are improving,</strong> consider prescribing a second course of intravaginal clotrimazole or miconazole.</li><li><strong>Do not prescribe an oral antifungal drug.</strong></li></ul></li><li><strong>Reinforce <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/management/during-pregnancy/#general-advice-on-self-management\">self-management advice</a>.</strong></li><li><strong>Refer or seek specialist advice if:</strong><ul><li>The person is aged 12–15 years.</li><li>Compliance has been a problem because of adverse effects.</li><li>Symptoms are not improving and treatment failure is unexplained.</li><li>There is doubt about the diagnosis.</li><li>Non-albicans <em>Candida </em>species has been identified.</li><li>Treatment fails again.</li></ul></li></ul></li></ul><!-- end field 55d7b310-3f54-4a43-ad09-5c82dee3f017 --><!-- end item d4f24006-d45c-4dfb-87ea-7617554d1ed8 -->","subChapters":[{"id":"6d2cedcb-3a0d-5470-93e8-d12fe9f058e7","slug":"basis-for-recommendation-fc6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 785c54e4-a119-4aee-a3a1-756671285ade --><h4>Basis for recommendation</h4><!-- end field 785c54e4-a119-4aee-a3a1-756671285ade -->","summary":null,"htmlStringContent":"<!-- begin item fc67044a-7eb0-4035-b13e-13ddbc901484 --><!-- begin field 5bf69998-8bef-4835-b1a4-7206f08c9c2a --><p>CKS found no evidence or national guidelines specifically on treatment failure of vulvovaginal candidiasis in pregnancy. These recommendations are largely based on what CKS considers to be good clinical practice.</p><h5>Confirming compliance with initial management </h5><ul><li>CKS recommends considering compliance with initial management, as treatment failure is more likely if there is poor compliance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Ringdahl, 2000</a>], although treatment failure is more common during pregnancy) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Sobel, 2007</a>].</li><li>Topical antifungals usually cause no systemic adverse effects, although local mild burning or irritation may occur [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>]. CKS recommends considering this in women with persisting symptoms.</li></ul><h5>Reassessing for other predisposing factors</h5><ul><li>CKS recommends reassessing for other predisposing factors, as treatment failure is more likely if there is continued exposure to predisposing factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">Ringdahl, 2000</a>].</li></ul><h5>Considering alternative diagnoses</h5><ul><li>The symptoms of vulvovaginal candidiasis are non-specific and may occur in women with other conditions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>]. CKS recommends considering alternative diagnoses if there is treatment failure, as misdiagnosis is a common cause for treatment failure.</li><li>The recommendations to send a vaginal specimen for microscopy, culture, and sensitivity and to consider measuring vaginal pH (if possible) are extrapolated from expert opinion in UK and US guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2006b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">FSRH, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">RCGP, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], which differ in their recommendations for laboratory tests for women with vulvovaginal candidiasis. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/candida-female-genital/diagnosis/assessment/#basis-for-recommendation-179\">Investigations</a> for more information.</li></ul><h5>Antifungal treatment</h5><ul><li>The recommendation on how to manage poor compliance is based on what CKS considers to be good clinical practice.</li><li>Oral antifungals are not recommended for use in pregnant women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">van Schalkwyk, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">NICE, 2016</a>].</li></ul><h5>Referral or seeking specialist advice</h5><ul><li>The recommendation to arrange referral or specialist advice for girls aged 12–15 years is based on the fact that management decisions for this age group are not straightforward:<ul><li>Intravaginal antifungal pessaries and cream are not recommended for pre-pubertal girls [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>].</li><li>The British National Formulary (BNF) for Children states that treatment with an external cream may be more appropriate in this age group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BNF for Children, 2017</a>]. CKS recommends referral or seeking specialist advice if this does not work.</li><li>Oral fluconazole is not licensed for treating vulvovaginal candidiasis in children younger than 16 years of age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2015c</a>].</li><li>Oral itraconazole is not licensed for use in children (age not specified by the manufacturer) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">ABPI, 2016b</a>].</li></ul></li><li>The recommendation to arrange referral or seek specialist advice if non-albicans <em>Candida</em> species is identified is based on expert opinion in guidelines issued by the British Association of Sexual Health and HIV (BASHH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007b</a>] and the US Centers for Disease Control and Prevention (CDC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>], which state that:<ul><li>The optimal treatment of non-albicans vulvovaginal candidiasis is currently unknown. Options include longer duration of treatment (7–14 days) with a non-fluconazole azole regimen (oral or topical) as first-line treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">CDC, 2015</a>].</li><li>In some people with resistant organisms, treatments that should only be initiated by a specialist, or are difficult to obtain in primary care, may be required [<a class=\"bibliography-reference internal-reference\" href=\"/topics/candida-female-genital/references/\">BASHH, 2007d</a>].</li></ul></li><li>The other recommendations on when to arrange referral or seek specialist advice are based on what CKS considers to be good clinical practice.</li></ul><!-- end field 5bf69998-8bef-4835-b1a4-7206f08c9c2a --><!-- end item fc67044a-7eb0-4035-b13e-13ddbc901484 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}